Endocrine Abstracts

Thyroid cancer is the most common malignant tumor of the human endocrine system. Recently, its incidence has increased significantly. Anaplastic cancer constitutes 2–4% of thyroid cancers and remains aggressive. The life expectancy is 2–6 months. It is often beyond the surgical margin. External radiation therapy or chemotherapy are the treatment options. Therefore, new therapeutic approaches are needed. Peroxisome proliferator-activated receptor (PPAR) gamma is a DNA...

Medullar thyroid cancer (MTK) approximately constitutes 5% of thyroid cancer, over the 25% cases it progresses in familial form. In charge of genetic inherited clinical features in RET protooncogene ‘germ-line’ makes up activating mutations. In post RET mutation in association with tyrosine kinase activation oncogenic cell proliferation is increased. In medullary thyroid cancer persistent and recurrence disease management is complicated, because it is unresponsive to...